EMA
guidance
· 2024-11-15
Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids
Summary
EMA updated guidance to minimize the risk of serious interactions between Mysimba (naltrexone/bupropion) and opioid medicines. The agency notes that using opioi…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Use of opioid medicines with Mysimba may lead to serious side effects